Angelo Dipasquale: Which patient may benefit from inclusion in an early-phase trial with next-generation immunotherapies?

Angelo Dipasquale: Which patient may benefit from inclusion in an early-phase trial with next-generation immunotherapies?

Angelo Dipasquale,

“Which patient may benefit from inclusion in an early-phase trial with next-generation immunotherapies? Find out our experience with interesting observations and a handy prognostic nomogram for clinical practice.”

graphical user interface, text, application

Read further.

Source: Angelo Dipasquale/LinkedIn

Angelo Dipasquale cancer Humanitas Research Hospital immunotherapies OncoDaily Oncology